The short version of Ipamorelin fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-10-27. Anything still debated is marked as such rather than presented as settled.
Compared with other secretagogues such as GHRP-2, GHRP-6, and hexarelin, ipamorelin is described as more selective. Published animal work reports little or no increase in adrenocorticotropic hormone, cortisol, or prolactin at doses that release growth hormone. This selectivity is the property most often cited in the research literature. Whether the same profile holds across species and dosing schedules remains an open question, since human data are limited and come largely from small studies.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue family. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, and its molecular mass is approximately 711.9 daltons. The compound was described in the late 1990s by researchers seeking molecules that release growth hormone with fewer side effects than earlier secretagogues. It is a laboratory and research compound, not an approved medicine in most jurisdictions.
Published discussion of this compound is uneven. Some references describe it as a tool for probing growth hormone regulation, while others focus on analytical characterization or on comparisons with related secretagogues. Statements about selectivity, half-life and potency often trace back to a small number of original reports that later authors cite secondhand. Readers evaluating a claim should therefore check whether a figure reflects a direct measurement or a repeated citation, and whether the underlying study was conducted in animals, in isolated cells or in human volunteers.
Identity and purity assessment for a research peptide of this kind typically combines reversed-phase high-performance liquid chromatography with mass spectrometry. The chromatographic run separates related impurities and yields a purity percentage, while electrospray ionization or matrix-assisted laser desorption mass spectrometry confirms the expected molecular mass. Amino acid analysis or tandem mass spectrometry sequencing can add confidence when material is intended for quantitative work. Laboratories differ in how they calculate and report purity, so figures from different sources are not always directly comparable.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic pentapeptide | Growth hormone secretagogue family |
| Molecular mass | Approximately 711.9 Da | Free base, calculated value |
| Receptor target | GHS-R1a, the ghrelin receptor | Agonist activity reported |
| Sequence | Aib-His-D-2-Nal-D-Phe-Lys-NH2 | C-terminal amide |
| Reported selectivity | Little change in ACTH, cortisol, prolactin | Based mainly on animal data |
In the scientific literature, ipamorelin appears mainly in preclinical studies, receptor binding assays, and reviews of growth hormone secretagogues. Authors often discuss its selectivity profile alongside limitations such as small sample sizes, short study durations, and differences between species. Some papers examine pharmacokinetics and clearance, but human data are limited and not sufficient to define general clinical effects. Regulatory discussion treats the compound as an investigational or research substance rather than an approved therapy in most jurisdictions. Open questions include oral bioavailability, long-term endocrine effects, and whether selectivity observed in animals persists in humans.
Research peptides such as ipamorelin are commonly supplied as lyophilized powder and characterized by analytical certificates. Reversed-phase high-performance liquid chromatography is used to estimate purity by ultraviolet absorbance, while mass spectrometry confirms molecular identity and detects sequence-related impurities. Counterion content, water content, and residual synthesis reagents can affect the reported mass balance. A certificate of analysis may list a purity percentage, but that number depends on the analytical method and the definition of impurity peaks. Independent verification is often recommended because research supply chains vary in quality control practices.
Storage recommendations for ipamorelin usually focus on temperature, moisture, and light. Lyophilized powder is typically held at or below minus twenty degrees Celsius in a desiccated container protected from light. Reconstituted solutions are often aliquoted and stored at minus eighty degrees Celsius to reduce repeated freeze-thaw cycles, which can promote aggregation or degradation. The optimal buffer and pH depend on the specific assay, and no single condition applies to every experimental context. Peptide stability should be assessed with time-point measurements rather than assumed from general handling rules.
Activity is mediated mainly through the growth hormone secretagogue receptor, now generally called the ghrelin receptor or GHS-R1a. Binding at this G-protein-coupled receptor triggers phospholipase C signaling, calcium mobilization, and release of growth hormone from pituitary somatotrophs. Reports describe less pronounced stimulation of adrenocorticotropic hormone and prolactin compared with earlier secretagogues such as hexarelin or GHRP-6. Selectivity figures vary between assay systems, so the degree of separation from other secretagogues is an area of ongoing comparison rather than a fixed constant.
In animal and early human studies, ipamorelin produces pulsatile growth hormone release and a secondary rise in insulin-like growth factor 1. The magnitude and duration of that rise depend on route, sampling schedule, and the baseline endocrine state of the subject. Whether repeated exposure alters the response over time is not firmly settled, since some reports describe stable pulsatility while others note attenuation. Most published data come from small samples, which limits the strength of any general claim about long-term behavior.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class of compounds. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, a structure that differs from natural ghrelin in length and in the presence of non-natural amino acid residues. Early laboratory work described it as a comparatively selective agent that stimulates growth hormone release with limited effect on other pituitary hormones. The compound is supplied as a lyophilized solid for research use and has no identified natural source in the body.
Compared with earlier growth hormone secretagogues such as GHRP-6 and hexarelin, ipamorelin has been reported to produce less stimulation of adrenocorticotropic hormone, cortisol, and prolactin in animal and early human studies. This selectivity is usually attributed to differences in receptor subtype interactions and to the tissue distribution of the receptor. Effects on appetite appear weaker than those of ghrelin itself, although the supporting evidence base is small. Whether these differences produce a distinct clinical profile remains an open question, since controlled human trials are limited.
Ipamorelin is a synthetic pentapeptide first described in the 1990s by researchers at Novo Nordisk during a program to develop selective growth hormone secretagogues. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, incorporating two non-natural residues, alpha-aminoisobutyric acid and D-2-naphthylalanine. The C-terminus is amidated, and the material is supplied as a white lyophilized powder. The molecular formula is C38H49N9O5 and the monoisotopic mass is approximately 711.85 daltons. The short chain and modified residues give it greater resistance to enzymatic degradation than many larger peptide hormones.
Compared with older secretagogues such as hexarelin or GHRP-6, ipamorelin shows weaker stimulation of cortisol, prolactin, and appetite in the animal models used for early characterization. Whether that selectivity is preserved across longer human exposures remains an open question, because published clinical data are limited in size and duration. Reported effects on food intake are generally described as modest. The compound is therefore treated in the literature as a relatively selective research tool rather than a fully characterized therapeutic agent.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class of compounds. Researchers at a pharmaceutical company first described it in the 1990s while screening small peptides for growth hormone releasing activity. Its chain contains five amino acid residues, two of which are non-natural building blocks, including 2-aminoisobutyric acid and a naphthylalanine derivative. The molecule was designed to act at the ghrelin receptor while avoiding several effects observed with earlier secretagogues.
== Alkalinity of non-hydroxides == Bases are generally compounds that can neutralize an amount of acid. Both sodium carbonate and ammonia are bases, although neither of these substances contains OH− groups. Both compounds accept H+ when dissolved in protic solvents such as water:
=== Boer organization and skills === War was declared on 11 October with a Boer offensive into the British-held Natal and Cape Colony areas. The Boers had about 33,000 soldiers, and outnumbered the British, who could move only 13,000 troops to the front line. The Boers had no problems with mobilisation, since the independent Boers had no regular army units, apart from the Staatsartillerie (Dutch for 'State Artillery'). As with the First Boer War, since most of the Boers were members of civilian militias, none had adopted uniforms or insignia. Only the members of the Staatsartillerie wore light green uniforms.
== Ethical concerns == Advancements in recombinant DNA technology have revolutionized the idea of treating diseases through the reconstruction or replacement of faulty genes. Gene therapy is a technique that transplants normal genes into cells that contain missing or defective genes to correct genetic disorders. Nevertheless, several concerns have been raised about the efficacy of gene therapy due to its limited success rate in clinical trials. Over the years, immense efforts have been placed to fully understand vectors, viruses, and their communication with their host's immune system. However, not every defense system reacts the same. Some patients have experienced an "autoimmune-like" response where their body rejects this treatment. The heterologous genes are recognized as foreign to the host and can induce cytokine-mediated inflammatory responses that are ultimately destroyed by their cytotoxic T-cells. This has called into question the relationship between vector dosage and cellular toxicity as scientists recognize that inappropriate activation of these responses can cause severe side effects not only to the disease-infected cells but other healthy parts of the body. Genetic modification used to address concerns outside of medical necessities such as eye color, athletic abilities, intelligence, etc. is one example that has brought into question the ethicality of its purpose. Eugenics, which places a group of desirable human characteristics over another has led to fears of potential backlash toward genetically modified, or genetically unmodified individuals in society.
In the quarterfinals, he beat Borna Ćorić in four sets to reach his second major semifinal. There, he lost the first two sets to Pablo Carreño Busta, but came back to win the match in five; this was his first-ever match win from two sets down. He thus advanced to his first major final, where he faced Dominic Thiem. He became the runner-up, losing the final in a final-set tiebreaker despite leading by two sets and twice coming within two points of the title in the final set. Zverev was seeded 6th at the French Open. He beat Dennis Novak, Pierre-Hugues Herbert, and Marco Cecchinato, before losing in four sets to Jannik Sinner. In October, he won two consecutive ATP 250 events in Cologne, which took place in the 2020 ATP Tour because of the cancellation of several tournaments due to the COVID-19 pandemic. In the finals, he defeated Félix Auger-Aliassime and Diego Schwartzman, both in straight sets. Zverev then reached the final of the Paris Masters, beating Nadal in straight sets in the semifinals, where he lost to Daniil Medvedev in three sets. In the ATP Finals, Zverev was eliminated in the group stage after a three-set win over Diego Schwartzman, and straight-set losses to Djokovic and the eventual champion Medvedev.
Yemelyan Pugachev, a low-status Don Cossack, arrived in the Yaik Host in late 1772. There, he claimed to be Peter III, playing on the Cossack belief that Peter would have been an effective ruler but for his assassination in a plot by his wife, Catherine II. Many Yaik Cossacks believed Pugachev's claim, although those closest to him knew the truth. Others, who may have known of it, did not support Catherine II due to her disposal of Peter III, and also spread Pugachev's claim to be the late emperor. The first of three phases of Pugachev's Rebellion began in September 1773. Most of the rebels' first prisoners were Cossacks who supported the elite. After a five-month siege of Orenburg, a military college became Pugachev's headquarters. Pugachev envisioned a Cossack tsardom, similar to Razin's vision of a united Cossack republic. The peasantry across Russia stirred with rumors and listened to the manifestos Pugachev issued. But the rebellion soon came to be seen as an inevitable failure. The Don Cossacks refused to help the final phase of the revolt, knowing that military troops were closely following Pugachev after lifting the siege of Orenburg, and following his flight from defeated Kazan. In September 1774, Pugachev's own Cossack lieutenants turned him over to the government troops. Opposition to centralization of political authority led the Cossacks to participate in Pugachev's Rebellion. After their defeat, the Cossack elite accepted government reforms, hoping to secure status within the nobility.
Sources: en.wikipedia.org
Magnetic resonance angiography (MRA) generates pictures of the arteries to evaluate them for stenosis (abnormal narrowing) or aneurysms (vessel wall dilatations, at risk of rupture). MRA is often used to evaluate the arteries of the neck and brain, the thoracic and abdominal aorta, the renal arteries, and the legs (called a "run-off"). A variety of techniques can be used to generate the pictures, such as administration of a paramagnetic contrast agent (gadolinium) or using a technique known as "flow-related enhancement" (e.g., 2D and 3D time-of-flight sequences), where most of the signal on an image is due to blood that recently moved into that plane (see also FLASH MRI). Techniques involving phase accumulation (known as phase contrast angiography) can also be used to generate flow velocity maps easily and accurately. Magnetic resonance venography (MRV) is a similar procedure that is used to image veins. In this method, the tissue is now excited inferiorly, while the signal is gathered in the plane immediately superior to the excitation plane—thus imaging the venous blood that recently moved from the excited plane.
=== Other species === FPR receptors are widely distributed throughout mammalian species with the FPR1, FPR2, and FPR3 paralogs, based on phylogenetic analysis, originating from a common ancestor, early duplication of FPR1, and FPR2/FPR3 splitting with FPR3 originating from the latest duplication event near the origin of primates. Rabbits express an ortholog of FPR1 (78% amino acid sequence identity) with high binding affinity for FMLP; rats express an ortholog of FPR2 (74% amino acid sequence identity) with high affinity for lipoxin A4.
== Research == Bimatoprost has been used to treat eyebrow hypotrichosis in a 60-year old female. The 0.03% solution was applied topically once a day for eight months and showed "increased hair growth and thickening of the eyebrow hairs". Bimatoprost and its endogenous analog prostaglandin F2α ethanolamide present the side-effect of being anti-adipogenic, and have been shown to be inducers of preadipocyte proliferation. These findings suggest bimatoprost is a possible therapy for obesity.
LBT-3627 is an experimental peptide drug derived from vasoactive intestinal peptide (VIP) intended to modulate the behavior of immune cells in cases of neurodegenerative disease such that they protect dopamine-producing cells rather than attack them. The drug is currently being studied for its potential use in the treatment of Parkinson's disease.
intein Any sequence of one or more amino acids within a precursor polypeptide that is excised by protein splicing during post-translational modification and is therefore absent from the mature protein, analogous to the introns spliced out of RNA transcripts. Contrast extein.
Sources: en.wikipedia.org
Ipamorelin is a synthetic pentapeptide that stimulates growth hormone release by activating the ghrelin receptor. It is handled as a research tool rather than as a licensed therapeutic product. Its short chain length makes it comparatively simple to synthesize and analyze.
Both bind the same receptor, but ghrelin is a 28-amino-acid hormone with roles in appetite and energy balance. Ipamorelin is a much smaller synthetic peptide selected for growth hormone release with limited effect on appetite signaling in animal models. The full overlap between their effects is not completely mapped.
Most published data come from animal studies and a small number of human trials. Findings on growth hormone release are reasonably consistent, while long-term effects and direct comparisons with other secretagogues remain incompletely studied. Open questions include duration of action across different populations.
Reversed-phase liquid chromatography is standard for purity, and mass spectrometry is standard for identity. Amino acid analysis is used when quantitative composition matters. No single technique answers every question, so laboratories usually combine two or three.